Safety Profile and Regulatory Considerations for Research Use
According to the financial reports by Novo Nordisk, the business revenue of GLP-1 RAs has reached 34,653 million Danish krone (DKK) in the first quarter of 2023 ( The FDA Adverse Event Reporting System (FAERS) is a robust pharmacovigilance database that contains real-world data on AE reporting ( Methods Data sources FAERS is an openly accessible pharmacovigilance database documenting AEs, medication errors, and product quality complaints reported spontaneously by people of diverse occupations worldwide ( Data extraction In order to acquire AE reports data treated with GLP-1 RAs, we identified the AEs of GLP-1 RAs in the DRUG files using the generic and brand names of the FDA-approved GLP-1 RAs, specifically exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), lixisenatide (ADLYXIN, SOLIQUA), dulaglutide (TRULICITY), semaglutide (OZEMPIC, RYBELSUS, WEGOVY), and tirzepatide (MOUNJARO)

For example, the Krispy Kreme stock was downgraded by several investment banks from buy to hold, with the stock price dropping c.14% in the immediate wake of the SELECT trial announcement in August 2023 (from $14.40 to $12.43) due to the uncertain impact that the rise in weight-loss drugs will have on the future sales of the business
Glucose Homeostasis: Study enhanced insulin secretion and reduced hepatic gluconeogenesis
In Oregon, Eastern Curry County and Josephine County and Jackson County
What The Research Says If you have PCOS, you may know how frustrating weight loss can be